Adding the anti-malaria drug chloroquine to standard therapies may help combat resistance to therapy and also resensitize glioblastoma patients to targeted treatments that had previously stopped working.
Although previous clinical trials have demonstrated that antiangiogenetic chemotherapy is not effective in GBM, researchers conducted a retrospective of review of perfusion MR images to determine if a phenotypic subtype of GBM may respond to antiangiogenic chemotherapy.
An analysis of data from caregivers and patients participating in a longitudinal study funded by the National Institutes of Health examines whether caregivers' anxiety, depressive symptoms, burden, and mastery influence survival for patients with newly diagnosed glioblastoma multiforme.
Insurance status influences overall patient survival for some cancer types, but its impact on glioblastoma multiforme (GBM) survival is well documented. This research study explored the possible impact of insurance on GBM survival.
Despite the use of adjuvant chemotherapy, deferral of postoperative radiotherapy is associated with worse survival in pediatric patients with medulloblastoma.
Chimeric antigen receptor (CAR) T cells may have improved therapeutic potential when they have 2 targets, according to preclinical findings using a mouse model.
Benign brain tumors that have previously been associated with obesity and diabetes are surprisingly less likely to emerge in patients with high blood sugar, according to new research.
Gross total resection to treat glioblastoma multiforme (GBM) showed progression-free survival benefits over subtotal resection and biopsy in a meta-analysis of 37 studies.
The role of antiangiogenic agents continues to evolve in the treatment of CNS cancers, attendees were told in a poster discussion session at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting.
The 2016 WHO Classification of Infiltrating Gliomas alters diagnostic criteria, providing the basis for clinical trial inclusion or exclusion based on an integrated diagnosis and setting the stage for all future research, according to a summary of 4 posters related to CNS biomarkers presented at the ASCO 2016 Annual Meeting.
Discovery might eventually lead to better treatment for glioblastoma multiforme
Glioblastoma tumors were successfully infiltrated by investigational CAR therapy with an acceptable safety profile.
The addition of chemotherapy to radiation therapy prolonged survival in adults with grade 2 glial brain tumors.
The altered metabolism of methionine, tryptophan, kynurenine, and 5-methylthioadenosine can drive the development of glioblastoma. Results also suggest ways to treat the cancer, slow its growth, and precisely elucidate its extent.
The growth of medulloblastoma was inhibited by a new drug in research conducted in cell cultures and mice. This study targeted a particularly aggressive form of the disease driven by the oncogene MYC.
A next-generation immunotherapy may offer hope for treating high-grade glioma, an aggressive form of brain cancer that is notoriously hard to treat.
A new therapy might help treat a rare, high-risk cancer that begins development in the fetus or embryo, neuroblastoma, according to recent results from cell culture experiments.
Adding panobinostat to radiotherapy appears safe, tolerable, and has preliminary efficacy for treating recurrent high-grade gliomas.
Bevacizumab plus irinotecan significantly improved the 6-month progression-free survival (PFS) rate and median progression-free survival.
This technique, which does not use pharmaceutical sedatives, can ease the perioperative discomfort and anxiety experienced by some patients undergoing fully awake craniotomy to remove glioma.
Detailed new information about diffuse glioma has come from an international collaborative study, raising hopes for improved clinical outcomes from a better understanding of the disease.
A past history of psychiatric disorders has been linked to suicidal ideation in patients with brain tumors.
New genetic testing can assist brain cancer treatment planning.
Treating medulloblastoma with proton beam therapy results in survival rates in line with other proton therapies, according to recent study data.
Phase 2 trial data showed acceptable toxicity and similar survival as conventional radiotherapy for childhood medulloblastoma.
Valproic acid and levetiracetam do not improve survival outcomes in patients with newly diagnosed glioblastoma, according to a recently published study.
New Studies Reveal Long-Term Vision-related Health Concerns of Survivors of Childhood Retinoblastoma and Brain CancerJanuary 11, 2016
Two new studies investigate the impact of retinoblastoma on long-term health of survivors and the long-term psychological and socio-economic effects of blindness in survivors of brain tumors.
Progression-free and overall survival were prolonged with electromagnetic field and chemotherapy maintenance therapy in patients with a brain tumor.
A noninvasive, low-cost blood test was developed to help doctors diagnose some types of malignant childhood tumor. It could also enable treatment monitoring without exposing patients to repeated doses of radiation.
Glioma Cells Self-organize Into Streams of Cells That Follow a Mathematically Predicted Pattern to Build Brain TumorsDecember 29, 2015
Brain tumor cells can self-organize, according to new research. Glioma cells build tumors by self-organizing into streams 10 to 20 cells wide that obey a mathematically predicted pattern for autonomous agents flowing together.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- Patients With Urologic Cancer Need Psycho-oncologic Support to Manage High Stress
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|